Trial · NCT07910669
The Effectiveness of Pilates Exercise on Chronic Low Back Pain of The Older Adults
NCT07910669, Not applicable, Completed, National Yang Ming Chiao Tung University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effectiveness of Pilates Exercise on Chronic Low Back Pain of The Older Adults. Trials, record NCT07910669. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910669
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effectiveness of Pilates Exercise on Chronic Low Back Pain of The Older Adults
- NCT number
- NCT07910669
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 50 participants, actual
- Lead sponsor
- National Yang Ming Chiao Tung University
- Conditions
- Chronic Low-back Pain
- Interventions
- Pilates exercise
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain was measured using a visual analogue scale (VAS). | A total of three measurements were taken (one baseline and two post-tests at 4 and 8 weeks post-intervention). | The visual analogue scale consists of a 10-cm line, each labelled at the left end as 'no pain' (0) and at the right end as 'very severe pain' (10).Patients were asked to draw a vertical mark on each line(Delgado et al., 2018). |
| Primary | Disability was assessed using the Oswestry Disability Index (ODI). | A total of three measurements were taken (one baseline and two post-tests at 4 and 8 weeks post-intervention). | Disability was assessed using the Oswestry Disability Index. It contains ten items related to limitations in daily life activities, rating each on a 0-5 point scale; the points are added together and converted into a percentage:Minimally disabled (0-10%), moderately disabled(20-40%), severely disabled (40-60%), crippled (60-80%) or bedbound (80-100%)(Rocchi et al., 2005). |
| Secondary | The Beck Depression Scale was used to measure the severity of depressive symptoms among patients(Dworkin et al., 2008). | A total of three measurements were taken (one baseline and two post-tests at 4 and 8 weeks post-intervention). | The BDI consists of 21 groups of four statements designed to assess the severity of current depressive symptoms, with a total score ranging from 0 to 63. Beck and Steer suggested that scores below 10 should be considered to reflect "mild or none" depression, 10 to 18, 19 to 29, and 30 to 63 to reflect "mild to moderate," "moderate to severe," and "severe" depression, respectively (Beck et al., 1988). |
| Secondary | Muscle power measured by microFET3. | A total of three measurements were taken (one baseline and two post-tests at 4 and 8 weeks post-intervention). | Muscle power measured by microFET3. Patient Position: Lying on their side with the test leg up. At the start of the test, the limb is slightly extended beyond the midline, and the pelvis is slightly rotated forward. The lower leg is bent for stability. Therapist Position: Standing behind the patient. The hand applying resistance is placed on the lateral side near the ankle. The hand used to palpate the gluteus medius is placed proximal to the greater trochanter of the femur. Instructions to the Patient: "Lift your leg. Hold it. Don't let me press it down." |
| Secondary | Hip mobility measured using a GEMRED brand, model: 82311-300 electronic protractor. | A total of three measurements were taken (one baseline and two post-tests at 4 and 8 weeks post-intervention). | The range of free movement a joint can make during body movement. It is the number of arc degrees of movement between the start and end of a movement on a specific plane. |
| Secondary | The Chinese version of the self-efficacy for exercise (SEE-C) scale | A total of two measurements were taken ( baseline and 8 weeks post-intervention). | The Chinese version of the self-efficacy for exercise (SEE-C) scale was designed to test people's confidence to continue exercising in the face of barriers to exercise (Lee et al., 2009).It attempts to predict and explain human behavior by referencing an individual's assessment of their ability or effectiveness in successfully performing a specific behavior. Self-efficacy theory suggests that the stronger an individual's self-efficacy and outcome expectations, the more likely they are to initiate and persist in a specific activity. Self-efficacy theory includes self-efficacy expectations, which are an individual's beliefs about their ability to perform a series of actions to achieve a desired outcome, and the belief that their actions will produce a certain result. |
| Secondary | Patient Global Impression of Change (PGIC) scale | A total of two measurements were taken ( 4 and 8 weeks post-intervention). | Symptom improvement satisfaction is one of the core outcome indicators of overall improvement after treatment. This study used the Patient Global Impression of Change scale (PGIC). Participants were required to rate on a scale from -5 to 5, with each number representing a different condition: 0 represents "no change," -5 represents "very bad," -4 to -1 represent varying degrees of "worse," with lower numbers indicating a worse condition. 1 to 4 represent varying degrees of "recovery," with higher numbers indicating a better condition. 5 represents "complete recovery," meaning the patient has fully recovered to a normal state (Kamper et al., 2009). The Patient-Assessed Overall Improvement Scale is completed by the patient themselves to self-assess the severity of the disease or the effectiveness of the treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910669
GET https://conductscience.org/api/trials/v1/NCT07910669/registered